

John A Carucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/869749/publications.pdf>

Version: 2024-02-01

46
papers

1,494
citations

448610

19
h-index

355658

38
g-index

47
all docs

47
docs citations

47
times ranked

2436
citing authors

#	ARTICLE	IF	CITATIONS
1	A cohort study to determine factors associated with upstaging cutaneous squamous cell carcinoma during Mohs surgery. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 191-194.	0.6	4
2	Scalp nodule in a 59-year-old female. <i>International Journal of Dermatology</i> , 2021, 60, e166-e168.	0.5	0
3	Current concepts and approaches to merkel cell carcinoma. <i>Archives of Dermatological Research</i> , 2021, 313, 129-138.	1.1	7
4	Skin Cancers and Lung Transplant. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 483-496.	0.8	1
5	Modified operations to permit safe and timely delivery of essential surgical care for high-risk skin cancer during a pandemic.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21565-e21565.	0.8	0
6	Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients. <i>JAMA Dermatology</i> , 2021, 157, 1219.	2.0	24
7	Use of Adjuvant Radiotherapy in the Treatment of High-risk Cutaneous Squamous Cell Carcinoma With Perineural Invasion. <i>JAMA Dermatology</i> , 2020, 156, 918.	2.0	17
8	Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma. <i>Npj Precision Oncology</i> , 2020, 4, 13.	2.3	20
9	MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation. <i>PLoS ONE</i> , 2020, 15, e0241551.	1.1	6
10	A 3D biofabricated cutaneous squamous cell carcinoma tissue model with multi-channel confocal microscopy imaging biomarkers to quantify antitumor effects of chemotherapeutics in tissue. <i>Oncotarget</i> , 2020, 11, 2587-2596.	0.8	17
11	Title is missing!. , 2020, 15, e0241551.		0
12	Title is missing!. , 2020, 15, e0241551.		0
13	Title is missing!. , 2020, 15, e0241551.		0
14	Title is missing!. , 2020, 15, e0241551.		0
15	Evidence-Based Clinical Practice Guidelines for Management of Microcystic Adnexal Carcinoma. <i>JAMA Dermatology</i> , 2019, 155, 1009.	2.0	3
16	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. <i>Transplant International</i> , 2019, 32, 1268-1276.	0.8	44
17	Skin cancer in transplant recipients: Scientific retreat of the international immunosuppression and transplant skin cancer collaborative and skin care in organ transplant patientsâ€”Europe. <i>Clinical Transplantation</i> , 2019, 33, e13736.	0.8	9
18	Stratification of Poor Outcomes for Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients Using the American Joint Committee on Cancer Eighth Edition and Brigham and Women's Hospital Staging Systems. <i>Dermatologic Surgery</i> , 2019, 45, 1117-1124.	0.4	17

#	ARTICLE	IF	CITATIONS
19	Expertise in Head and Neck Cutaneous Reconstructive Surgery. <i>Dermatologic Surgery</i> , 2019, 45, 782-790.	0.4	5
20	Real-world Merkel cell carcinoma outcomes from a tertiary care center.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14098-e14098.	0.8	0
21	Outcomes in MAGE+ cutaneous squamous cell carcinoma with perineural invasion treated with surgery followed by postoperative radiation therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21043-e21043.	0.8	0
22	Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	27
23	Repair of a Large Defect Involving the Nose, Cheek, and Upper Cutaneous Lip. <i>Dermatologic Surgery</i> , 2018, 44, 1631-1634.	0.4	1
24	Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. <i>JAMA Dermatology</i> , 2017, 153, 299.	2.0	88
25	Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma. <i>Dermatologic Clinics</i> , 2017, 35, 73-84.	1.0	17
26	V-Y Advancement Flap for Defects of the Lidâ€“Cheek Junction. <i>Facial Plastic Surgery</i> , 2017, 33, 329-333.	0.5	7
27	Digital imaging biomarkers feed machine learning for melanoma screening. <i>Experimental Dermatology</i> , 2017, 26, 615-618.	1.4	25
28	MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 775-778.	0.3	12
29	Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. <i>JCI Insight</i> , 2016, 1, e86434.	2.3	34
30	Metastatic Cutaneous Squamous Cell Carcinoma: The Importance of T2 Stratification and Hematologic Malignancy in Prognostication. <i>Dermatologic Surgery</i> , 2016, 42, 932-935.	0.4	17
31	Use of Digitally Stained Multimodal Confocal Mosaic Images to Screen for Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016, 152, 1335.	2.0	29
32	An Inferiorly Based Rotation Flap for Defects Involving the Lower Eyelid and Medial Cheek. <i>Facial Plastic Surgery</i> , 2015, 31, 411-416.	0.5	12
33	Gene Expression Profiling of the Leading Edge of Cutaneous Squamous Cell Carcinoma: IL-24-Driven MMP-7. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1418-1427.	0.3	53
34	SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma. <i>Nature Communications</i> , 2014, 5, 4511.	5.8	100
35	CD200 Upregulation in Vascular Endothelium Surrounding Cutaneous Squamous Cell Carcinoma. <i>JAMA Dermatology</i> , 2013, 149, 178.	2.0	35
36	Skin Cancer in Immunosuppressed Patients. <i>Facial Plastic Surgery</i> , 2013, 29, 402-410.	0.5	23

#	ARTICLE	IF	CITATIONS
37	Increased Tc22 and Treg/CD8 Ratio Contribute to Aggressive Growth of Transplant Associated Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e62154.	1.1	68
38	Understanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immunotherapy. Clinical and Developmental Immunology, 2013, 2013, 1-14.	3.3	42
39	Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity. Journal of Investigative Dermatology, 2012, 132, 1645-1655.	0.3	35
40	VEGF-C-producing macrophages in cutaneous squamous cell carcinoma. Expert Review of Dermatology, 2011, 6, 643-651.	0.3	1
41	The Human Cutaneous Squamous Cell Carcinoma Microenvironment Is Characterized by Increased Lymphatic Density and Enhanced Expression of Macrophage-Derived VEGF-C. Journal of Investigative Dermatology, 2011, 131, 229-236.	0.3	100
42	Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated. Journal of Investigative Dermatology, 2011, 131, 1322-1330.	0.3	160
43	Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. Journal of Investigative Dermatology, 2011, 131, 1322-30.	0.3	81
44	Immunosuppression Affects CD4+ mRNA Expression and Induces Th2 Dominance in the Microenvironment of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. Journal of Immunotherapy, 2010, 33, 538-546.	1.2	39
45	Human Langerhans cells induce distinct IL-22-producing CD4 ⁺ T cells lacking IL-17 production. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21795-21800.	3.3	227
46	Myeloid Dendritic Cells from Human Cutaneous Squamous Cell Carcinoma Are Poor Stimulators of T-Cell Proliferation. Journal of Investigative Dermatology, 2009, 129, 2451-2462.	0.3	79